Newronika secures EUR 13.6 million in Series B financing round
Marc Nemitz
| 13.02.2025
The new funds will advance the development of adaptive deep brain stimulation (DBS) for the treatment of Parkinson's disease and enable more precise, personalized therapy.
Milan, February 13, 2025 - Medtech company Newronika, a leader in deep brain stimulation (DBS) for the treatment of Parkinson's disease, has successfully closed a €13.6 million Series B funding round. The round was led by Fondazione ENEA Tech e Biomedical, with further participation from existing investors such as Indaco Venture Partners SGR, Innogest SGR and Wille Finance.
Capital inflow strengthens Newronika's position
The funds received will be used to advance the development and clinical validation of Newronika's adaptive DBS platform. The innovative system aims to provide Parkinson's patients with more precise and personalized therapy by integrating real-time data and machine learning into the treatment process. The funding will also help to further develop product pipelines, recruit talent and foster strategic collaborations.
This funding round reinforces our commitment to transform the way deep brain stimulation is delivered. Our vision is to enable a more precise and personalized Parkinson's therapy.
Dr. Lorenzo Rossi, co-founder and CEO of Newronika
Partnership with the Michael J. Fox Foundation and IDE approval
The successful funding round underscores Newronika's momentum, which is reinforced by the support of institutions such as the Michael J. Fox Foundation and IDE approval. The company aims to bring about a fundamental change in neuromodulation and focuses on personalized treatment approaches that can improve the quality of life of Parkinson's patients.
Newronika's adaptive DBS system has the potential to revolutionize the treatment of movement disorders worldwide.
Maria Cristina Porta, General Manager of Fondazione ENEA Tech e Biomedical
Further expansion of the clinical and commercial phases
Newronika not only receives financial support, but also strategic partnerships for the further expansion of the technology. Davide Turco, CEO of Indaco, emphasized: "Indaco is proud to continue to support Newronika in the upcoming clinical and commercial phases. We are convinced that the adaptive DBS system will significantly improve the quality of life of Parkinson's patients." The successful Series B financing not only strengthens Newronika financially, but also positions the company as an important player in the field of neuromodulation technologies.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectTake care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.
Share on Linkedin Share on Facebook Share on XingFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
